Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.
CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.
Stocktwits on MSN
MRNA stock rallies over 40% in June: Moderna bets its future on cancer, autoimmune disease and AI-powered mRNA
At Science Day, Moderna outlined growth plans across infectious-disease vaccines, Intismeran, and rare-disease therapeutics. ...
Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in ...
Provides broad overview of Company's research and early development programs expected to continue to fuel future ...
Moderna just received fantastic news.
Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...
The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to ...
Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company famous, ...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Among all the awards and mementos Moderna ...
mCOMBRIAX is the world’s first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna’s fourth vaccine to receive a positive ...
The company's pending vaccine approvals could help the stock continue its rise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results